quinagolide
Trade name: Norprolac
Small moleculeexperimental
Quinagolide (INNTooltip International nonproprietary name, BANTooltip British Approved Name), sold under the brand name Norprolac, is a selective dopamine D2 receptor agonist which is used to manage hyperprolactinemia. It has also been found to be effective in the treatment of breast pain. It is used in the UK, but it is not available in US. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
1
Earliest trial started Jun 1, 2006 (NCT00329693)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Dopamine D2 receptorAGONIST
DRD2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21- Mol. weight
- 395.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaQuinagolide ↗
- ChEMBLCHEMBL290962 ↗
- ChEMBLCHEMBL2218861 ↗
Also known as
- cv 205-502
- cv-205-502
- cv205-502
- cv205-502
- cv205-502
- n,n-diethyl-n'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide, (3alpha,4aalpha,10abeta)-(+-)-isomer
- n,n-diethyl-n'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide hydrochloride, (3alpha,4aalpha,10abeta)-(+)-isomer
- (+-)-n,n-diethyl-n'-((3r*,4ar*,10as*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamide
- (+-)-n,n-diethyl-n'-((3r*,4ar*,10as*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamide
- norprolac
- norprolac
- norprolac
- norprolac
- quinagolida
- quinagolida
- quinagolide
- quinagolide
- quinagolide
- quinagolide
- quinagolide
- quinagolide
- quinagolide
- quinagolide
- quinagolide, (3alpha,4aalpha,10abeta)-(+-)-isomer
- quinagolide hydrochloride
- quinagolide hydrochloride
- quinagolide hydrochloride, (3alpha,4aalpha,10abeta)-(+)-isomer
- quinagolide hydrochloride, 3alpha,4aalpha,10abeta-(-)-isomer
- quinagolidum
- quinagolidum
- sdz 205-502
- sdz 205-502
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03749109 | Phase 2 | Jun 21, 2019 | Ferring |
| NCT04107480 | Phase 4 | Jun 21, 2019 | Leiden University |
| NCT03692403 | Phase 2 | Oct 31, 2018 | Ferring |
| NCT00665041 | Phase 2 | May 1, 2008 | University of Valencia |
| NCT00329693 | Phase 2 | Jun 1, 2006 | Ferring |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 3 | 3 | 1 | 2006 |
| Leiden University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Valencia | Academic/Hospital | 1 | 1 | 1 | 2008 |
3 organizations
Page 1 / 1